Targeting CDKN2A in Mesothelioma

被引：0
|
作者：
Fennell, D. [1 ,2 ]
机构：
[1] Univ Leicester, Leicester Canc Res Ctr, Mesothelioma Res Programme, Leicester, Leics, England
[2] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
CDKN2A MTAP synthetic lethality;
D O I：
10.1016/j.jtho.2019.08.078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES03.02
引用
收藏
页码：S18 / S19
页数：3
相关论文
共 50 条
  • [1] Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma
    Kreuger, Inger Z. M.
    Slieker, Roderick C.
    van Groningen, Tim
    van Doorn, Remco
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (01) : 18 - +
  • [2] CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition
    Pinton, Giulia
    Wang, Zhuo
    Balzano, Cecilia
    Missaglia, Sara
    Tavian, Daniela
    Boldorini, Renzo
    Fennell, Dean A.
    Griffin, Martin
    Moro, Laura
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Correlation of MTAP Immunohistochemistry with CDKN2A and MTAP Genomic Alterations in Malignant Mesothelioma
    Sholl, Lynette
    Dubuc, Adrian
    Hornick, Jason
    Chapel, David
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1819 - 1819
  • [4] CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
    Illei, PB
    Ladanyi, M
    Rusch, V
    Zakowski, M
    MODERN PATHOLOGY, 2002, 15 (01) : 75A - 75A
  • [5] CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
    Betti, M.
    Aspesi, A.
    Biasi, A.
    Casalone, E.
    Ferrante, D.
    Ogliara, P.
    Gironi, L. C.
    Giorgione, R.
    Farinelli, P.
    Grosso, F.
    Libener, R.
    Rosato, S.
    Turchetti, D.
    Maffe, A.
    Casadio, C.
    Ascoli, V.
    Dianzani, C.
    Colombo, E.
    Piccolini, E.
    Pavesi, M.
    Miccoli, S.
    Mirabelli, D.
    Bracco, C.
    Righi, L.
    Boldorini, R.
    Papotti, M.
    Matullo, G.
    Magnani, C.
    Pasini, B.
    Dianzani, I.
    CANCER LETTERS, 2016, 378 (02) : 120 - 130
  • [6] CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
    Illei, PB
    Ladanyi, M
    Rusch, V
    Zakowski, M
    LABORATORY INVESTIGATION, 2002, 82 (01) : 75A - 75A
  • [7] Correlation of MTAP Immunohistochemistry with CDKN2A and MTAP Genomic Alterations in Malignant Mesothelioma
    Sholl, Lynette
    Dubuc, Adrian
    Hornick, Jason
    Chapel, David
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1819 - 1819
  • [8] Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre
    Marshall, Kelly
    Jackson, Susan
    Jones, Jennifer
    Holme, Jayne
    Lyons, Judith
    Barrett, Emma
    Taylor, Paul
    Bishop, Paul
    Hodgson, Clare
    Green, Michael
    Telford, Nicholas
    Evison, Matthew
    LUNG CANCER, 2020, 150 : 195 - 200
  • [9] TP53 and CDKN2A Mutations Correlate with Survival, Stage, and Grade in Mesothelioma
    Zhu, Allen
    Husain, Aliya
    Hermina, Andrew
    Mueller, Jeffrey
    Kwon, Jung Woo
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1972 - S1973
  • [10] Targeting MAT2A in CDKN2A/MTAP-deleted cancers
    Marjon, Katya
    Kalev, Peter
    Hyer, Marc
    Fletcher, Mark
    Zhang, Peili
    Aguado-Fraile, Elia
    Mandley, Everton
    Konteatis, Zenon
    Travins, Jeremy
    Marks, Kevin
    CANCER RESEARCH, 2019, 79 (13)
12345